Drug Information

Drug General Information
Drug ID
D07XUY
Former ID
DNC007017
Drug Name
8-methylnaringenin
Drug Type
Small molecular drug
Indication Discovery agent Investigative [528557]
Structure
Download
2D MOL

3D MOL
Formula
C16H14O5
Canonical SMILES
CC1=C(C=C(C2=C1OC(CC2=O)C3=CC=C(C=C3)O)O)O
InChI
1S/C16H14O5/c1-8-11(18)6-12(19)15-13(20)7-14(21-16(8)15)9-2-4-10(17)5-3-9/h2-6,14,17-19H,7H2,1H3/t14-/m0/s1
InChIKey
GMVYLXBMPRDZDR-AWEZNQCLSA-N
PubChem Compound ID
44418717
Target and Pathway
Target(s) Estrogen receptor beta Target Info Inhibitor [528557]
Estrogen receptor Target Info Inhibitor [528557]
KEGG Pathway Estrogen signaling pathway
Prolactin signaling pathwayhsa04915:Estrogen signaling pathway
Prolactin signaling pathway
Thyroid hormone signaling pathway
Endocrine and other factor-regulated calcium reabsorption
Proteoglycans in cancer
NetPath Pathway FSH Signaling Pathway
EGFR1 Signaling Pathway
RANKL Signaling Pathway
Pathway Interaction Database Plasma membrane estrogen receptor signaling
Validated nuclear estrogen receptor beta network
Validated nuclear estrogen receptor alpha networksmad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
Signaling events mediated by HDAC Class II
LKB1 signaling events
Regulation of Telomerase
ATF-2 transcription factor network
AP-1 transcription factor network
FOXM1 transcription factor network
Validated nuclear estrogen receptor alpha network
Signaling mediated by p38-alpha and p38-beta
FOXA1 transcription factor network
Reactome Nuclear Receptor transcription pathwayR-HSA-1251985:Nuclear signaling by ERBB4
Nuclear Receptor transcription pathway
WikiPathways SIDS Susceptibility Pathways
Ovarian Infertility Genes
Integrated Pancreatic Cancer Pathway
Nuclear ReceptorsWP712:Estrogen signaling pathway
Nuclear Receptors Meta-Pathway
Estrogen Receptor Pathway
Signaling by ERBB4
JAK/STAT
Leptin signaling pathway
miR-targeted genes in muscle cell - TarBase
Integrated Breast Cancer Pathway
Nuclear Receptors
References
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.